EUVIMEDEUVIMED entdecken
Crossref

Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients

Amita Kulkarni iD, Luiza Perez, Lauren Mitchell, Muhammad Danyal Ahsan, Jesse Brewer iD, Charlene Thomas, Eloise Chapman-Davis, Evelyn Cantillo, Kevin Holcomb, Shoshana Rosenberg, Melissa K Frey

The Journal of Sexual Medicine · 2025

DOI: 10.1093/jsxmed/qdaf256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Sexual Medicine, 2025. Verfasst von Amita Kulkarni und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Weill Cornell Medicine, New York, NY 10065, United States. Hauptthemen laut MEDLINE: Sexual Health, Sexual Dysfunction, Physiological, Mass Screening. Die Arbeit nennt 48 Literaturangaben. Gefördert von: NCATS NIH HHS, Clinical and Translational Science Center at Weill Cornell Medical College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Risk-reducing salpingo-oophorectomy for ovarian cancer risk reduction in individuals with BRCA1/2 pathogenic variants can cause sexual dysfunction, yet sexual health discussions between patients and providers remain limited.

Aim

We describe the feasibility of universal sexual health screening and rates of sexual health dysfunction among individuals with BRCA1/2 pathogenic variants.

Methods

Patients with BRCA1/2 pathogenic variants presenting to an outpatient gynecologic oncology clinic from January 2022 to February 2023 were offered a sexual health screener. The screener combined a validated, single-item sexual dysfunction assessment with three additional questions exploring discussions of sexual health with healthcare providers, desire for information about sexual health, and preferred methods for delivery of information. Outcomes The primary outcome was the proportion of patients who completed the sexual health screener and the secondary outcomes included rate of sexual dysfunction and impact of patient characteristics on sexual dysfunction.

Results

Among 103 patients offered the sexual health screening, 100% completed it. Median age was 42 years (range 25-84). Eighty three (81%) patients self-identified as White, 32 (31%) patients had a history of cancer, 42 (41%) had undergone risk-reducing salpingo-oophorectomy, and 47 (46%) were pre-menopausal. Thirty seven (36%) patients screened positive for sexual dysfunction. Among patients with premature menopause following salpingo-oophorectomy, 6/15 (40%) on hormone replacement therapy reported sexual dysfunction versus 6/10 (60%) not on hormone replacement therapy (P = .43). Across all patients, 38 (37%) had never previously discussed sexual health concerns with a provider. There were no significant differences in sexual dysfunction rates based on any measured patient characteristics. Clinical Implications Universal sexual health screening for individuals with BRCA1/2 pathogenic variants is feasible and may provide an avenue for more in-depth discussion with at-risk patients, who may not have previously discussed this issue with their medical team. Strengths and Limitations Our study found that it was feasible to administer a sexual health screening tool among an at-risk patient population in a clinical setting. Generalizability may be limited due to the composition of our cohort, which was small, majority White and non-Hispanic, and from a single institution.

Conclusion

Providers should consider implementing standardized sexual health screening practices among patients with BRCA1/2 pathogenic variants. Research highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sexual HealthSexual Dysfunction, PhysiologicalMass ScreeningHumansFemaleMiddle AgedAdultAgedFeasibility StudiesAged, 80 and overSalpingo-oophorectomyOvarian NeoplasmsBRCA2 ProteinBRCA1 Protein

Stichwörter der Autor:innen

BRCAhereditary cancer syndromessexual dysfunction

Substanzen

BRCA2 protein, humanBRCA2 ProteinBRCA1 protein, humanBRCA1 Protein

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division of Gynecology Oncology, Weill Cornell Medicine, New York, NY 10065, United States.
  • Department of Population Health Sciences, Weill Cornell Medical College, New York, NY 10065, United States.

ORCID-Profile: Amita Kulkarni, Jesse Brewer

Förderung

  • NCATS NIH HHS
  • Clinical and Translational Science Center at Weill Cornell Medical College

Zitieren

APA

Kulkarni, A., Perez, L., Mitchell, L., Ahsan, M. D., Brewer, J., Thomas, C., Chapman-Davis, E., Cantillo, E., Holcomb, K., Rosenberg, S., & Frey, M. K. (2025). Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients. The Journal of Sexual Medicine. https://doi.org/10.1093/jsxmed/qdaf256

Vancouver

Kulkarni A, Perez L, Mitchell L, Ahsan MD, Brewer J, Thomas C, et al. Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients. The Journal of Sexual Medicine. 2025. doi:10.1093/jsxmed/qdaf256

BibTeX
@article{Kulkarni2025,
  author = {Kulkarni, Amita and Perez, Luiza and Mitchell, Lauren and Ahsan, Muhammad Danyal and Brewer, Jesse and Thomas, Charlene and Chapman-Davis, Eloise and Cantillo, Evelyn and Holcomb, Kevin and Rosenberg, Shoshana and Frey, Melissa K},
  title = {Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients},
  journal = {The Journal of Sexual Medicine},
  year = {2025},
  doi = {10.1093/jsxmed/qdaf256}
}
Kostenlos starten →